RATIONALE: Schizophrenic patients show deficits in pre-attentive information processing as evidenced, for example, by disrupted prepulse inhibition, a measure of sensorimotor gating. A similar disruption can be observed in animals treated with the psychotomimetic agent, phencyclidine (PCP). However, the mechanism by which PCP alters brain function has not been fully elucidated. Recent studies have demonstrated that certain behavioural and neurochemical effects of PCP in rats and mice are blocked by nitric oxide (NO) synthase inhibition, suggesting an important role for NO in the effects of PCP. OBJECTIVE: The aim of the present study was to investigate the effects of PCP on cAMP production in the ventral hippocampus and the role of NO in these effects using in vivo microdialysis in rats. Furthermore, the effects of PCP on acoustic startle reactivity and prepulse inhibition of acoustic startle were compared with changes in cAMP levels in the ventral hippocampus. RESULTS: Significant increases in cAMP levels were observed in the ventral hippocampus following both local infusion (10(-4) mol/l and 10(-3) mol/l) and systemic administration (2 mg/kg) of PCP. The PCP-induced changes in prepulse inhibition and startle reactivity were associated in magnitude and duration with the increase in cAMP levels in the hippocampus. Furthermore, systemic administration of the NO synthase inhibitor, L: -NAME (10 mg/kg), blocked both the changes in cAMP levels and the behavioural responses induced by PCP. CONCLUSIONS: These findings indicate that the effects of PCP on prepulse inhibition and startle reactivity are associated with an increase in cAMP levels in the ventral hippocampus, and that this change in cAMP response may be linked to the production of NO.
RATIONALE: Schizophrenicpatients show deficits in pre-attentive information processing as evidenced, for example, by disrupted prepulse inhibition, a measure of sensorimotor gating. A similar disruption can be observed in animals treated with the psychotomimetic agent, phencyclidine (PCP). However, the mechanism by which PCP alters brain function has not been fully elucidated. Recent studies have demonstrated that certain behavioural and neurochemical effects of PCP in rats and mice are blocked by nitric oxide (NO) synthase inhibition, suggesting an important role for NO in the effects of PCP. OBJECTIVE: The aim of the present study was to investigate the effects of PCP on cAMP production in the ventral hippocampus and the role of NO in these effects using in vivo microdialysis in rats. Furthermore, the effects of PCP on acoustic startle reactivity and prepulse inhibition of acoustic startle were compared with changes in cAMP levels in the ventral hippocampus. RESULTS: Significant increases in cAMP levels were observed in the ventral hippocampus following both local infusion (10(-4) mol/l and 10(-3) mol/l) and systemic administration (2 mg/kg) of PCP. The PCP-induced changes in prepulse inhibition and startle reactivity were associated in magnitude and duration with the increase in cAMP levels in the hippocampus. Furthermore, systemic administration of the NO synthase inhibitor, L: -NAME (10 mg/kg), blocked both the changes in cAMP levels and the behavioural responses induced by PCP. CONCLUSIONS: These findings indicate that the effects of PCP on prepulse inhibition and startle reactivity are associated with an increase in cAMP levels in the ventral hippocampus, and that this change in cAMP response may be linked to the production of NO.
Authors: Daniel Klamer; Erik Pålsson; Aron Revesz; Jörgen A Engel; Lennart Svensson Journal: Psychopharmacology (Berl) Date: 2004-06-02 Impact factor: 4.530
Authors: Thomas J Gould; Scott P Bizily; Jan Tokarczyk; Michele P Kelly; Steven J Siegel; Stephen J Kanes; Ted Abel Journal: Neuropsychopharmacology Date: 2004-03 Impact factor: 7.853
Authors: Béatrice Marcelin; Zhiqiang Liu; Yuncai Chen; Alan S Lewis; Albert Becker; Shawn McClelland; Dane M Chetkovich; Michele Migliore; Tallie Z Baram; Monique Esclapez; Christophe Bernard Journal: J Neurosci Date: 2012-03-14 Impact factor: 6.167
Authors: Kim Fejgin; Sergej Safonov; Erik Pålsson; Caroline Wass; Jörgen A Engel; Lennart Svensson; Daniel Klamer Journal: Psychopharmacology (Berl) Date: 2007-01-19 Impact factor: 4.530
Authors: Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff Journal: Psychopharmacology (Berl) Date: 2008-06-21 Impact factor: 4.530
Authors: Ana C Issy; João Francisco C Pedrazzi; Bruno H Yoneyama; Elaine A Del-Bel Journal: Psychopharmacology (Berl) Date: 2013-10-08 Impact factor: 4.530
Authors: Michele P Kelly; Carolina Isiegas; York-Fong Cheung; Jan Tokarczyk; Xioaju Yang; Michael F Esposito; David A Rapoport; Sara A Fabian; Steven J Siegel; Gary Wand; Miles D Houslay; Stephen J Kanes; Ted Abel Journal: Neuropsychopharmacology Date: 2006-05-31 Impact factor: 7.853
Authors: Erik Pålsson; Kim Fejgin; Caroline Wass; Jörgen A Engel; Lennart Svensson; Daniel Klamer Journal: Psychopharmacology (Berl) Date: 2007-01-19 Impact factor: 4.415